Product Overview

Tenalip D 5/20 is a dual-action oral antidiabetic formulation containing Dapagliflozin Propanediol Monohydrate 5 mg and Teneligliptin Hydrobromide Hydrate IP 20 mg, developed for the effective management of Type 2 Diabetes Mellitus. This advanced combination therapy brings together the benefits of an SGLT2 inhibitor and a DPP-4 inhibitor to provide comprehensive blood glucose control through complementary mechanisms of action.

Dapagliflozin works by reducing glucose reabsorption in the kidneys, allowing excess glucose to be eliminated through urine, while Teneligliptin enhances the body’s natural incretin system by increasing glucose-dependent insulin secretion and reducing glucagon release. Together, these mechanisms help achieve effective control of both fasting and postprandial blood glucose levels while maintaining a low risk of hypoglycemia when used as prescribed.

Tenalip D 5/20 is commonly recommended for patients whose blood glucose levels are not adequately controlled with diet, exercise, and monotherapy. It may also be incorporated into long-term diabetes management plans alongside healthy lifestyle modifications and regular blood glucose monitoring. The combination therapy offers convenient once-daily dosing, improves treatment adherence, and supports better metabolic control.

Manufactured under stringent pharmaceutical quality standards, Tenalip D 5/20 delivers consistent efficacy, safety, and reliability, making it a trusted therapeutic option for healthcare professionals managing Type 2 Diabetes Mellitus.

How It Works

Dapagliflozin selectively inhibits Sodium-Glucose Co-Transporter 2 (SGLT2) in the kidneys, promoting urinary glucose excretion and lowering blood glucose levels independently of insulin. Teneligliptin inhibits the DPP-4 enzyme, increasing incretin hormone levels that stimulate glucose-dependent insulin secretion and suppress glucagon release. Together, these complementary mechanisms provide comprehensive glycemic control while supporting improved metabolic health.

Therapeutic Applications

Tenalip D 5/20 may be prescribed for the management of:

• Type 2 Diabetes Mellitus
• Inadequately Controlled Blood Glucose Levels
• Long-Term Glycemic Management
• Combination Antidiabetic Therapy
• Cardiovascular Risk Reduction in appropriate patients
• Patients requiring dual-mechanism glucose control

Key Benefits

• Dual-action therapy for comprehensive blood glucose management.
• Combines Dapagliflozin and Teneligliptin in a single tablet.
• Helps control both fasting and postprandial blood glucose levels.
• Promotes urinary glucose excretion and glucose-dependent insulin secretion.
• Convenient once-daily dosing to improve treatment adherence.
• Manufactured under stringent pharmaceutical quality standards.

Quality Commitment

Vinix Biopharma is committed to delivering high-quality antidiabetic medicines manufactured in accordance with stringent pharmaceutical quality standards. Tenalip D 5/20 undergoes comprehensive quality assurance and rigorous testing to ensure safety, efficacy, consistency, and reliability. Every batch is carefully evaluated to maintain product integrity and support optimal patient care.

Storage Information

Store in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Disclaimer

Tenalip D 5/20 should be used only under the supervision of a qualified healthcare professional. Dosage and duration of treatment should be determined by the treating physician based on the patient’s clinical condition, medical history, and therapeutic requirements.